Loading...
•
Jun 30, 2022
InspireMD Q2 2022 Earnings Report
InspireMD reported second quarter 2022 financial results, demonstrating revenue growth and progress in key markets.
Key Takeaways
InspireMD reported a 47.6% increase in total revenue for the second quarter of 2022, driven by a 47.8% increase in CGuard EPS sales volume. The company is progressing with its U.S. IDE trial and anticipates full enrollment by approximately Q1 of next year.
Total revenue increased by 47.6% to $1,531,000 compared to Q2 2021.
CGuard EPS sales volume increased by 47.8% to $1,505,000 compared to Q2 2021.
Gross profit increased by 64.4% to $431,000 compared to Q2 2021.
Net loss totaled $4,636,000, or $0.59 per share, compared to a net loss of $3,507,000, or $0.46 per share, for the same period in 2021.
InspireMD
InspireMD
InspireMD Revenue by Segment
Revenue by Segment
CGuard EPS Revenue
CapyFin.com Forward Guidance
InspireMD anticipates future growth driven by continued market share gains, geographic expansion, and new stent delivery systems.
Positive Outlook
- Continued market share gains
- Additional geographic expansion
- Introduction of new stent delivery systems
- Acceleration of enrollment in the U.S. IDE trial
- Anticipated full enrollment in the U.S. IDE trial by approximately Q1 of next year
Challenges Ahead
- Market acceptance of existing and new products
- Negative clinical trial results or lengthy product delays in key markets
- Inability to secure regulatory approvals for the sale of products
- Intense competition in the medical device industry
- Product liability claims